Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oopherectomy

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Abstract

The contractor will conduct a pre-surgical 2-arm pilot study to evaluate the effect of 3-4 monthly doses of denosumab on proliferation of fallopian tube epithelial cells in pre-menopausal women carrying a BRCA1/2 mutation.